GSK FY Conference Summary Company Overview - **Company**: GSK (NYSE:GSK) - **Event**: 2026 J.P. Morgan Healthcare Conference - **Date**: January 13, 2026 Key Industry Insights R&D Achievements - GSK achieved **13 positive phase 3 readouts** in 2024 and **5 out of 5 approvals** in 2025, indicating strong pipeline execution [3][4] - The company anticipates **15 scale launches** with potential peak sales exceeding **$2 billion** by 2031, supported by a pipeline of approximately **25 assets** [3][4] Notable Drug Approvals - **Depemokimab (Xtensia)**: First ultra-long-acting biologic for respiratory disease, effective in reducing severe exacerbations in eosinophilic asthma by **70%** with only two administrations per year [4] - **Nucala**: Approved for COPD, preventing **35%** of exacerbations leading to hospitalization, addressing a significant healthcare burden in the U.S. with **1.8 million ED visits** annually [5] - **Blenrep**: Approved in the U.S. for third-line treatment of myeloma, with a market projected to grow from **$20 billion** to **$40 billion** by the end of the decade [48] Pipeline and Future Developments - GSK is focusing on **chronic hepatitis B** with a potential **15%-20% functional cure** in selected populations, a significant advancement after 30 years [7][9] - The company plans to initiate **up to 10 new pivotal studies** in 2026, continuing to build on the momentum of its late-stage development pipeline [10] R&D Productivity and Technology - GSK's end-to-end success rates from preclinical to approval have more than **doubled since 2018** [13] - Cycle times for major market approvals have halved from **2021 to 2024**, indicating improved efficiency in R&D processes [14] - The application of **AI and machine learning** is being utilized to enhance R&D efficiency, particularly in reducing attrition rates at phase two and improving target selection [16][17] Business Development and Collaborations - GSK is actively pursuing business development opportunities, focusing on assets that can drive near-term sales by **2031** [22] - Recent collaborations include partnerships with **Boston Pharmaceuticals** and **Summit** to enhance their pipeline [22][23] Market Insights and Patient Impact - The launch of **Xtensia** is expected to become standard care for severe eosinophilic asthma, with **80%** of pulmonologists recognizing its potential [26] - GSK is addressing the unmet needs in **refractory chronic cough**, with **28 million patients** globally, and aims to provide a significant improvement in treatment options [40][41] Oncology Developments - **Blenrep** is positioned as a convenient treatment option for myeloma patients, with a focus on community use where **70%** of patients are treated [49] - The company is exploring further studies to expand Blenrep's use into second-line and first-line treatments, with potential re-filing by **2028** [50] Conclusion GSK is demonstrating strong momentum in its R&D pipeline with significant drug approvals and a focus on innovative treatments across various therapeutic areas. The company is leveraging technology to enhance productivity and is committed to addressing unmet medical needs in chronic diseases and oncology.